Literature DB >> 17160376

[Psoriatic arthritis].

Edmund Cauza1, Attila Dunky.   

Abstract

This article presents an overview of psoriatic arthritis, including the origin, genetic influence and immunologic factors involved in its evolution. The clinical features of psoriatic arthritis are also reviewed in this article, and a discussion of the diagnosis and treatment is included. We have highlighted the current psoriasis treatments, new biological therapies, and their use in practice. This paper reviews the efficacy of these agents, and the importance of their early appliance. The available published data on the efficacy of antimalarials, sulfasalazine, methotrexate, azathioprine and ciclosporin are described, as well as new data on leflunomide and other novel agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17160376     DOI: 10.1007/s10354-006-0276-7

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  59 in total

1.  Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.

Authors:  F Van den Bosch; E Kruithof; D Baeten; F De Keyser; H Mielants; E M Veys
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

Review 2.  Interventions for psoriatic arthritis.

Authors:  G Jones; M Crotty; P Brooks
Journal:  Cochrane Database Syst Rev       Date:  2000

3.  Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate.

Authors:  A L Ogilvie; C Antoni; C Dechant; B Manger; J R Kalden; G Schuler; M Lüftl
Journal:  Br J Dermatol       Date:  2001-03       Impact factor: 9.302

4.  Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis.

Authors:  P Rahman; E Nguyen; C Cheung; C T Schentag; D D Gladman
Journal:  J Rheumatol       Date:  2001-05       Impact factor: 4.666

5.  Interactions of lymphocytes from patients with psoriatic arthritis or healthy controls and cultured endothelial cells.

Authors:  A Dunky; J Neumüller; J Menzel
Journal:  Clin Immunol Immunopathol       Date:  1997-12

6.  The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991.

Authors:  M Shbeeb; K M Uramoto; L E Gibson; W M O'Fallon; S E Gabriel
Journal:  J Rheumatol       Date:  2000-05       Impact factor: 4.666

7.  PERB11 (MIC): a polymorphic MHC gene is expressed in skin and single nucleotide polymorphisms are associated with psoriasis.

Authors:  G K Tay; J Hui; S Gaudieri; M Schmitt-Egenolf; O P Martinez; C Leelayuwat; J F Williamson; T H Eiermann; R L Dawkins
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

8.  Overexpression of monocyte-derived cytokines in active psoriasis: a relation to coexistent arthropathy.

Authors:  A Nishibu; G W Han; K Iwatsuki; T Matsui; M Inoue; H Akiba; R Kaneko; F Kaneko
Journal:  J Dermatol Sci       Date:  1999-09       Impact factor: 4.563

Review 9.  Interleukin-15: a new cytokine target for the treatment of inflammatory diseases.

Authors:  Iain B McInnes; J Alastair Gracie
Journal:  Curr Opin Pharmacol       Date:  2004-08       Impact factor: 5.547

10.  Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.

Authors:  J Peter Kaltwasser; Peter Nash; Dafna Gladman; Cheryl F Rosen; Frank Behrens; Peter Jones; Jürgen Wollenhaupt; Franziska G Falk; Philip Mease
Journal:  Arthritis Rheum       Date:  2004-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.